TPEX:4197

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Market Cap

NT$440.6m

Last Updated

2021/06/17 08:36 UTC

Data Sources

Company Financials

Executive Summary

Visgeneer Inc., a biotech company, develops and produces biomedical products in the fields of medical device, cosmetics/skin care, bacterial fermentation, and cancer gene identification. More Details


Snowflake Analysis

Questionable track record with imperfect balance sheet.

Share Price & News

How has Visgeneer's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4197 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: 4197's weekly volatility has decreased from 26% to 5% over the past year.


Market Performance


7 Day Return

0.7%

4197

2.8%

TW Medical Equipment

1.3%

TW Market


1 Year Return

20.2%

4197

-5.1%

TW Medical Equipment

48.5%

TW Market

Return vs Industry: 4197 exceeded the TW Medical Equipment industry which returned -5.9% over the past year.

Return vs Market: 4197 underperformed the TW Market which returned 48.1% over the past year.


Shareholder returns

4197IndustryMarket
7 Day0.7%2.8%1.3%
30 Day-2.7%12.6%8.1%
90 Day13.2%13.9%8.0%
1 Year20.2%20.2%-2.9%-5.1%53.3%48.5%
3 Year-1.4%-1.4%16.3%6.6%75.9%55.7%
5 Year-31.1%-31.8%8.6%-5.6%140.8%97.9%

Long-Term Price Volatility Vs. Market

How volatile is Visgeneer's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Visgeneer undervalued compared to its fair value and its price relative to the market?

730.77x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate 4197's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate 4197's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: 4197 is poor value based on its PE Ratio (730.8x) compared to the TW Medical Equipment industry average (20.1x).

PE vs Market: 4197 is poor value based on its PE Ratio (730.8x) compared to the TW market (17.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4197's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4197's PB Ratio (2x) is in line with the TW Medical Equipment industry average.


Future Growth

How is Visgeneer forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

18.9%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Visgeneer has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Visgeneer performed over the past 5 years?

-31.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4197 has a large one-off gain of NT$3.4M impacting its December 31 2020 financial results.

Growing Profit Margin: 4197 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 4197 has become profitable over the past 5 years, growing earnings by -31.6% per year.

Accelerating Growth: 4197 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 4197 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (9.9%).


Return on Equity

High ROE: 4197's Return on Equity (0.3%) is considered low.


Financial Health

How is Visgeneer's financial position?


Financial Position Analysis

Short Term Liabilities: 4197's short term assets (NT$217.9M) exceed its short term liabilities (NT$72.5M).

Long Term Liabilities: 4197's short term assets (NT$217.9M) exceed its long term liabilities (NT$171.5M).


Debt to Equity History and Analysis

Debt Level: 4197's debt to equity ratio (96.3%) is considered high.

Reducing Debt: 4197's debt to equity ratio has increased from 53.9% to 96.3% over the past 5 years.

Debt Coverage: 4197's debt is not well covered by operating cash flow (3.6%).

Interest Coverage: Insufficient data to determine if 4197's interest payments on its debt are well covered by EBIT.


Balance Sheet


Dividend

What is Visgeneer current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4197's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4197's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4197's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4197's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: 4197 is not paying a notable dividend for the TW market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4197's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

Visgeneer has no CEO, or we have no data on them.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Visgeneer Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Visgeneer Inc.
  • Ticker: 4197
  • Exchange: TPEX
  • Founded: NaN
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: NT$440.642m
  • Shares outstanding: 30.18m
  • Website: https://www.visgeneer.com.tw

Number of Employees


Location

  • Visgeneer Inc.
  • No. 335, Zhonghua Road
  • Section 6
  • Hsinchu City
  • 30094
  • Taiwan

Listings


Biography

Visgeneer Inc., a biotech company, develops and produces biomedical products in the fields of medical device, cosmetics/skin care, bacterial fermentation, and cancer gene identification. The company offers...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/06/17 08:36
End of Day Share Price2021/06/15 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.